Insuline und Insulintherapie bei Kindern und Jugendlichen mit Diabetes mellitus

Zusammenfassung

Die Behandlung des Typ-1-Diabetes von Kindern und Jugendlichen hat mit der Entwicklung kurz und lang wirkender Insulinanaloga und der Einführung der Insulinpumpentherapie auch in diesem Alter viele neue Facetten erhalten. Mit der Vielfalt an möglichen Behandlungsschemata ist eine individuelle, auf den Patienten und dessen Familie zugeschnittene Insulintherapie möglich. Die Wahl des Behandlungsregimes sollte immer auch abhängig von den Wünschen und Fähigkeiten des Patienten und seiner Eltern besprochen werden.

Summary

In treatment of type 1 diabetes in children and adolescents new facets of treatment regimen are available with the introduction of new insulin analogs and pump therapy. A very individual treatment is possible with this variety of treatment options. Anyway the choice of regimen should be discussed with the patient and parents especially regarding the wishes and skills of the individual patient.

Schlüsselwörter

Typ-1-Diabetes mellitus - Insulintherapie - Insulinanaloga

Keywords

Type 1 diabetes - insulin therapy - insulin analogues

• Literatur

• 1 Birkebaek NH, Johansen A, Solvig J. Diabet Med 1998; 15: 965-71.
• 2 Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-6.
• 3 Danne T, Beyer P, Holl RW. et al. Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Leitlinien der DDG.
• 4 Danne T, Deiss D, Hopfenmüller W. et al. Experience with insulin analogues in children. Horm Res 2002; 57 (Suppl. 01) 46-53.
• 5 Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of longterm complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-881.
• 6 The Diabetes Control and Complications Trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
• 7 Hanas R. Selection for and initiation of continuous subcutaneous insulin infusion. Horm Res 2002; 57 (Suppl. 01) 101-4.
• 8 Hamilton J, Cummings E, Zdravkovic V. et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care 2003; 26: 138-43.
• 9 Hannonen R, Tupola S, Ahonen T. et al. Neurocognitive functioning in children with type 1 diabetes with and without episodes of severe hypoglycaemia. Dev Med Child Neurol 2003; 45: 262-8.
• 10 Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 04: 673-82.
• 11 Hershey T, Lillie R, Sadler M. et al. The effect of severe hypoglycaemia on cognition in children and adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab 2002; 15: 426-9.
• 12 Herwig J, Wernicke-Panten K. Niedrige Nüchternblutzucker durch Insulin Glargin (HOE901) bei Kindern und Jugendlichen mit Typ-1-Diabetes bei geringerem Risiko nächtlicher Hypoglykämien. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 01) S185.
• 13 Holl RW, Teller WM, Heinze E. Semilente – insulin is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type I diabetes. Exp Clin Endocrinol Diabetes 1996; 104: 360-4.
• 14 Kapellen TM, Galler A, Kiess W. Insulin Treatment. In: Chiarelli F, Dahl-Jorgensen K, Kiess W. Diabetes in Childhood and Adolescence. Basel: Karger Verlag; 2005: 122-38.
• 15 Kurtzhals P, Schaffer L, Sorensen A. et al. Correlation of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 2000; 49: 999-1005.
• 16 Litton J, Rice A, Friedman N. et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141: 490-5.
• 17 Ratner RE, Hirsch IB, Neifing JL. et al. Less hypoglycemia with Insulin Glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-43.
• 18 Sarnblad S, Kroon M, Aman J. Metformin as an additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003; 149: 232-329.
• 19 Schober E, Schoenle E, Van Dyk J, Wernicke-Panthen K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 369-76.
• 20 Siebenhofer A, Plank J, Berghold A. et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. In: The Cochrane Library. Issue 2, 2004 Chichester, UK: John Wiley & Sons, Ltd; 2004
• 21 Tupola S, Komulainen J, Jääskelainen J, Sipilä I. Post-prandial lispro vs. Post-prandial lispro vs. Diabetic medicine 2001; 18: 654-8.
• 22 Wintergerst KA, Hargadon S, Hsiang HY. Continuous subcutaneous insulin infusion in neonatal diabetes mellitus. Pediatric Diabetes 2005; 05: 202-4.
• 23 Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-87.
• 24 Weintrob N, Benzaquen H, Galatzer A. et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003; 112: 559-64.